|
Title
|
|
|
|
Histopathological growth patterns and tumor-infiltrating lymphocytes in breast cancer liver metastases
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Liver is the third most common organ for breast cancer (BC) metastasis. Two main histopathological growth patterns (HGP) exist in liver metastases (LM): desmoplastic and replacement. Although a reduced immunotherapy efficacy is reported in patients with LM, tumor-infiltrating lymphocytes (TIL) have not yet been investigated in BCLM. Here, we evaluate the distribution of the HGP and TIL in BCLM, and their association with clinicopathological variables and survival. We collect samples from surgically resected BCLM (n = 133 patients, 568 H&E sections) and post-mortem derived BCLM (n = 23 patients, 97 H&E sections). HGP is assessed as the proportion of tumor liver interface and categorized as pure-replacement ('pure r-HGP') or any-desmoplastic ('any d-HGP'). We score the TIL according to LM-specific guidelines. Associations with progression-free (PFS) and overall survival (OS) are assessed using Cox regressions. We observe a higher prevalence of 'any d-HGP' (56%) in the surgical samples and a higher prevalence of 'pure r-HGP' (83%) in the post-mortem samples. In the surgical cohort, no evidence of the association between HGP and clinicopathological characteristics is observed except with the laterality of the primary tumor (p value = 0.049) and the systemic preoperative treatment before liver surgery (p value = .039). TIL is less prevalent in 'pure r-HGP' as compared to 'any d-HGP' (p value = 0.001). 'Pure r-HGP' predicts worse PFS (HR: 2.65; CI: (1.45-4.82); p value = 0.001) and OS (HR: 3.10; CI: (1.29-7.46); p value = 0.011) in the multivariable analyses. To conclude, we demonstrate that BCLM with a 'pure r-HGP' is associated with less TIL and with the worse outcome when compared with BCLM with 'any d-HGP'. These findings suggest that HGP could be considered to refine treatment approaches. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
NPJ breast cancer. - New York, NY, 2015, currens
| |
|
Publication
|
|
|
|
New York, NY
:
Breast Cancer Research Foundation
,
2023
| |
|
ISSN
|
|
|
|
2374-4677
| |
|
DOI
|
|
|
|
10.1038/S41523-023-00602-6
| |
|
Volume/pages
|
|
|
|
9
:1
(2023)
, p. 1-11
| |
|
Article Reference
|
|
|
|
100
| |
|
ISI
|
|
|
|
001125772800001
| |
|
Pubmed ID
|
|
|
|
38102162
| |
|
Medium
|
|
|
|
E-only publicatie
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|